Perioperative celecoxib improves postoperative resting pain and active ROM after TKR .
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(2):48 BMC Musculoskelet Disord. 2008 Jun 3;9:77.80 patients scheduled to undergo total knee arthroplasty were randomized to receive celecoxib perioperatively along with the morphine PCA or just the morphine PCA. The purpose of this study was to evaluate efficacy of postoperative pain management. The perioperative celecoxib was found to significantly improve the postoperative resting pain scores at 48 and 72 hours and active ROM in the first three days after total knee arthroplasty. It also decreased the opioid consumption, without any increase in the occurrence of bleeding.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Yes = 1
Uncertain = 0.5
Not Relevant = 0
No = 0
The Reporting Criteria Assessment evaluates the transparency with which authors report the methodological and trial characteristics of the trial within the publication. The assessment is divided into five categories which are presented below.
2/4
Randomization
3/4
Outcome Measurements
4/4
Inclusion / Exclusion
4/4
Therapy Description
3/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
The Fragility Index is a tool that aids in the interpretation of significant findings, providing a measure of strength for a result. The Fragility Index represents the number of consecutive events that need to be added to a dichotomous outcome to make the finding no longer significant. A small number represents a weaker finding and a large number represents a stronger finding.
Why was this study needed now?
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most common medications chiefly used for multimodal pain management. Celecoxib is a newer selective COX-2 inhibitor with improved efficacy and lesser side effects. This study evaluated the opioid-sparing effects and post operative pain control after total knee arthroplasty.
What was the principal research question?
How does oral celecoxib compare to patient controlled analgesia with morphine in post-operative pain management after total knee arthroscopy?
- Resting VAS pain scores improved significantly with the celecoxib compared to control treatment at 48 hrs (2.13
- +/- 1.68 vs. 3.43+/-1.50, p=0.03) and 72 hrs (1.78+/-1.66 vs. 3.17+/-2.01, p=0.02) after surgery. Moreover, the resting VAS pain reduction was more significant with celecoxib versus the control (p=0.023).
- Active ROM increased significantly in the celecoxib group, particularly in the first 72 hrs [40.8°+/-17.3° vs. 25.8°+/-11.5°, p=0.01 (day 1); 60.7°+/-18.1° vs. 45.0°+/-17.3°, p=0.004 (day 2); 77.7°+/-15.1° vs. 64.3°+/-16.9°, p=0.004 (day 3)]. Moreover, improvement in ROM was significantly greater with celecoxib versus the control (p=0.0009).
- With the celecoxib use, the opioid requirements (PCA morphine) decreased by 40% (p=0.03). Furthermore, the number of patients suffering from post-operative nausea/vomiting decreased from 43% in control group to 28% in celecoxib group - this was non significant (p=0.57).
- There were no differences in the perioperative blood losses between the groups; the patients on celecoxib had no greater requirement for blood transfusions.
What should I remember most?
The perioperative celecoxib was found to significantly improve the postoperative resting pain scores at 48 and 72 hrs and active ROM in the first three days after total knee arthroplasty, while decreasing the opioid consumption without any increase in the occurrence of bleeding.
How will this affect the care of my patients?
Celecoxib will serve as a good analgesic choice according to the study results. Caution should be exercised for their interpretation, keeping in mind the small sample size studied. The long-term effects require further research.
DISCLAIMER
This content found on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you require medical treatment, always seek the advice of your physician or go to your nearest emergency department. The opinions, beliefs, and viewpoints expressed by the individuals on the content found on this page do not reflect the opinions, beliefs, and viewpoints of OrthoEvidence.
0 of 4 monthly FREE articles unlocked
